Clinical trial · Interventional
Impact of Biliopancreatic Limb Length on Diabetes Following Distal Gastrectomy
Impact of the Length of Biliopancreatic Limb on Diabetes Associated With the Changes in Incretin Hormone and Gut Microbiota Following Distal Gastrectomy in Patients With Gastric Cancer and Type 2 Diabetes
NCT04889859CI-TRIAL-00064686completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective, randomized controlled trial to investigate the impact of a long biliopancreatic limb of Roux-en-Y reconstruction on diabetes control in patients with concurrent type 2 diabetes and gastric cancer
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diabetes Mellitus, Type 2 | — | UNRESOLVED | — |
| Stomach Neoplasm | Gastric Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| long biliopancreatic limb Roux-en-Y reconstruction | Procedure | — | UNRESOLVED |
| long Roux limb Roux-en-Y reconstruction | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- long RL group
- description
- long Roux limb Roux-en-Y reconstruction
- interventionNames
- Procedure: long Roux limb Roux-en-Y reconstruction
- type
- EXPERIMENTAL
- label
- long BPL group
- description
- long biliopancreatic limb Roux-en-Y reconstruction
- interventionNames
- Procedure: long biliopancreatic limb Roux-en-Y reconstruction
Primary outcomes (1)
- measure
- diabetes remission rate (%)
- timeFrame
- 6 months
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed with type 2 diabetes as well as pathologically proven gastric cancer of clinical stage I according to the AJCC 8th edition * Those who are expected to undergo laparoscopic distal gastrectomy Exclusion Criteria: 1. baseline fasting C-peptide level \< 1.0 ng/dL (who had the possibility of type 1 diabetes) 2. previous radiotherapy or surgery at upper abdomen other than laparoscopic cholecystectomy 3. other malignancies in recent 5 years 4. vulnerable patients (pregnant women, those with cognitive impairment, etc) 5. ECOG-PS ≥ 2 6. participating in other clinical trials within 6 months
References
Publications (0)
Data not yet available
No reference posted for this study.